Signal Transduction and Targeted Therapy · Nov 9, 2026
Mutant KRAS vaccination for pancreatic cancer interception: the G12D immunogenicity paradox
By Holmström MO, Hübbe ML, Chen IM et al.
In a recent study published in Cancer Discovery , Haldar and colleagues report the first-in-human evaluation of a pooled mutant (Kirsten rat sarcoma viral oncogene homolog) KRAS peptide vaccine in individuals at high risk of pancreatic ductal adenocarcinoma (PDAC). Vaccination induced broad and durable mutant KRAS-specific T-cell responses in most participants, providing a proof of concept for targeting oncogenic driver mutations before invasive pancreatic cancer develops. 1